The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms

Clinical and Translational Allergy

Volumn 2, Issue 1, 2012, Pages 1-8

  Baumann, Ralf ^a   Rabaszowski, Matthaeus ^a   Stenin, Igor ^a   Gaertner Akerboom, Maria ^a   Scheckenbach, Kathrin ^a   Wiltfang, Jens ^b   Schipper, Joerg ^a   Wagenmann, Martin ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

IL 13; IL 31; Kinetics; Nasal allergen; Nasal secretion

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 31; POLLEN ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MALE; NASAL PRURITUS; NOSE OBSTRUCTION; NOSE SECRETION; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROVOCATION TEST; RHINOMANOMETRY; RHINORRHEA; SNEEZING; SYMPTOM; UPREGULATION;

EID: 85006320793     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/2045-7022-2-13     Document Type: Article

References (43)

1. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004, 5: 752-760.
2. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean M, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006, 117: 411-417. 10.1016/j.jaci.2005.10.033.
3. Dreuw A, Radtke S, Pflanz S, Lippok BE, Heinrich PC, Hermanns HM: Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem. 2004, 279: 36112-36120. 10.1074/jbc.M401122200.
4. Heise R, Neis MM, Marquardt Y, Joussen S, Heinrich PC, Merk HF, Hermanns HM, Baron JM: IL-31 receptor alpha expression in epidermal keratinocytes is modulated by cell differentiation and interferon gamma. J Invest Dermatol. 2009, 129: 240-243. 10.1038/jid.2008.183.
5. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Quaked N, Schaffartzik A, van de Veen W, Zeller S, Zimmermann M, Akdis CA: Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011, 127: 701-721. 10.1016/j.jaci.2010.11.050. e1-70
6. Niyonsaba F, Ushio H, Hara M, Yokoi H, Tominaga M, Takamori K, Kajiwara N, Saito H, Nagaoka I, Ogawa H, Okumura K: Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol. 2010, 184: 3526-3534. 10.4049/jimmunol.0900712.
7. Bilsborough J, Leung DYM, Maurer M, Howell M, Boguniewicz M, Boguniewcz M, Yao L, Storey H, LeCiel C, Harder B, Gross JA: IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006, 117: 418-425. 10.1016/j.jaci.2005.10.046.
8. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W: Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 19: 347-356.
9. Ip WK, Wong CK, Li MLY, Li PW, Cheung PFY, Lam CWK: Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. 2007, 122: 532-541. 10.1111/j.1365-2567.2007.02668.x.
10. Grimstad O, Sawanobori Y, Vestergaard C, Bilsborough J, Olsen UB, Grønhøj-Larsen C, Matsushima K: Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. Exp Dermatol. 2009, 18: 35-43. 10.1111/j.1600-0625.2008.00766.x.
11. Schulz F, Marenholz I, Fölster-Holst R, Chen C, Sternjak A, Baumgrass R, Esparza-Gordillo J, Grüber C, Nickel R, Schreiber S, Stoll M, Kurek M, Rüschendorf F, Hubner N, Wahn U, Lee Y: A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol. 2007, 120: 1097-1102. 10.1016/j.jaci.2007.07.065.
12. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC, Merk HF, Bosio A, Baron JM, Hermanns HM: Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006, 118: 930-937. 10.1016/j.jaci.2006.07.015.
13. Lei Z, Liu G, Huang Q, Lv M, Zu R, Zhang G, Feng Z, Huang B: SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy. 2008, 63: 327-332.
14. Okano M, Fujiwara T, Higaki T, Makihara S, Haruna T, Noda Y, Kanai K, Kariya S, Yasueda H, Nishizaki K: Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis. J Allergy Clin Immunol. 2011, 127: 277-9. 10.1016/j.jaci.2010.09.029. 279.e1-11
15. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993, 362: 248-250. 10.1038/362248a0.
16. Shirakawa I, Deichmann KA, Izuhara I, Mao I, Adra CN, Hopkin JM: Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol Today. 2000, 21: 60-64. 10.1016/S0167-5699(99)01492-9.
17. Pawankar RU, Okuda M, Okubo K, Ra C: Lymphocyte subsets of the nasal mucosa in perennial allergic rhinitis. Am J Respir Crit Care Med. 1995, 152: 2049-2058.
18. Ghaffar O, Laberge S, Jacobson MR, Lowhagen O, Rak S, Durham SR, Hamid Q: IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. Am J Respir Cell Mol Biol. 1997, 17: 17-24.
19. Erin EM, Leaker BR, Zacharasiewicz AS, Higgins LA, Williams TJ, Boyce MJ, de Boer P, Durham SR, Barnes PJ, Hansel TT: Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. Allergy. 2005, 60: 1524-1529. 10.1111/j.1398-9995.2005.00928.x.
20. Miyahara S, Miyahara N, Matsubara S, Takeda K, Koya T, Gelfand EW: IL-13 is essential to the late-phase response in allergic rhinitis. J Allergy Clin Immunol. 2006, 118: 1110-1116. 10.1016/j.jaci.2006.06.014.
21. Bauchau V, Durham SR: Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004, 24: 758-764. 10.1183/09031936.04.00013904.
22. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010, 126: 466-476. 10.1016/j.jaci.2010.06.047.
23. Skoner DP: Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001, 108: S2-S8. 10.1067/mai.2001.115569.
24. Rondón C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, Mullol J, Blanca M: Local allergic rhinitis: Concept, pathophysiology, and management. J Allergy Clin Immunol. 2012, 129: 1460-1467. 10.1016/j.jaci.2012.02.032.
25. Wagenmann M, Schumacher L, Bachert C: The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy. 2005, 60: 1132-1138. 10.1111/j.1398-9995.2005.00867.x.
26. Naclerio RM, Proud D, Togias AG, Adkinson NF, Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM: Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985, 313: 65-70. 10.1056/NEJM198507113130201.
27. Baroody FM, Wagenmann M, Naclerio RM: Comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol. 1993, 74: 2661-2671.
28. Ruëff F, Bergmann K, Brockow K, Fuchs T, Grübl A, Jung K, Klimek L, Müsken H, Pfaar O, Przybilla B, Sitter H, Wehrmann W: Hauttests zur Diagnostik von allergischen Soforttyp-Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinischen Immunologie (DGAKI). Pneumologie. 2011, 65: 484-495. 10.1055/s-0030-1256476.
29. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet L, Bousquet P, Camargos P, Carlsen K, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim Y, Kowalski ML: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008, 63 (Suppl 86): 8-160.
30. Bousquet J, van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001, 108: S147-S334. 10.1067/mai.2001.118891.
31. Conover WJ: Practical nonparametric statistics. 1999, Wiley, New York, NY, [Applied probability and statistics section], 3
32. Perrigoue JG, Li J, Zaph C, Goldschmidt M, Scott P, de Sauvage FJ, Pearce EJ, Ghilardi N, Artis D: IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med. 2007, 204: 481-487. 10.1084/jem.20061791.
33. Perrigoue JG, Zaph C, Guild K, Du Y, Artis D: IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection. J Immunol. 2009, 182: 6088-6094. 10.4049/jimmunol.0802459.
34. Cheung PF, Wong C, Ho AW, Hu S, Chen D, Lam CW: Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010, 22: 453-467. 10.1093/intimm/dxq027.
35. Zürcher AW, Derer T, Lang AB, Stadler BM: Culture and IgE synthesis of nasal B cells. Int Arch Allergy Immunol. 1996, 111: 77-82. 10.1159/000237349.
36. KleinJan A, Dijkstra MD, Boks SS, Severijnen LA, Mulder PG, Fokkens WJ: Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. J Allergy Clin Immunol. 1999, 103: 441-450. 10.1016/S0091-6749(99)70469-0.
37. Laberge S, Durham SR, Ghaffar O, Rak S, Center DM, Jacobson M, Hamid Q: Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. J Allergy Clin Immunol. 1997, 100: 569-574. 10.1016/S0091-6749(97)70152-0.
38. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B: Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012, 91: 552-566. 10.1016/j.ejcb.2011.07.006.
39. de Vries JE, Carballido JM, Aversa G: Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol. 1999, 103: S492-S496. 10.1016/S0091-6749(99)70166-1.
40. Pawankar RU, Okuda M, Hasegawa S, Suzuki K, Yssel H, Okubo K, Okumura K, Ra C: Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. Am J Respir Crit Care Med. 1995, 152: 2059-2067.
41. Holgate ST, Polosa R: Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008, 8: 218-230. 10.1038/nri2262.
42. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007, 370: 1422-1431. 10.1016/S0140-6736(07)61600-6.
43. Venereau E, Diveu C, Grimaud L, Ravon E, Froger J, Preisser L, Danger Y, Maillasson M, Garrigue-Antar L, Jacques Y, Chevalier S, Gascan H: Definition and characterization of an inhibitor for interleukin-31. J Biol Chem. 2010, 285: 14955-14963. 10.1074/jbc.M109.049163.